[ad_1]
AstraZeneca says “positive high-level results” from the LAURA Phase III trial showed the company’s TAGRISSO demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival for patients with unresectable, Stage III epidermal growth factor receptor-mutated non-small cell lung cancer after chemoradiotherapy compared to placebo after CRT. Overall survival data showed a favorable trend for TAGRISSO, although data were not mature at the time of this analysis. The trial will continue to assess OS as a secondary endpoint. The safety and tolerability of TAGRISSO in the LAURA trial was consistent with its established profile and no new safety concerns were reported with TAGRISSO maintenance treatment following CRT. In addition, TAGRISSO plus chemotherapy was recently approved in the U.S. based on the FLAURA2 Phase III trial.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AZN:
[ad_2]
